Yarrow Bioscience (YARW) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 Nov, 2026Program and strategy
YB-101 is a potential first-in-class anti-TSHR antibody designed to block a shared disease mechanism in Graves’ disease (GD) and thyroid eye disease (TED).
The US Phase 2a/2b GD trial began in Q2 2026; Phase 2a proof-of-concept data are expected in 2H 2027, with Phase 2b expected to begin in 1H 2028.
FDA Fast Track designation was received for the GD program; the Phase 2a primary endpoint is safety and efficacy, including the percentage euthyroid and off anti-thyroid drugs (ATDs).
Exclusive rights cover all fields outside Greater China; GenSci received $70M upfront, with up to $1.295B in milestones and tiered royalties from low teens to low-mid teens.
Clinical evidence and development
In GenSci’s Phase 1 TED single-ascending-dose study, all adverse events were mild or moderate; no severe events, treatment-related serious adverse events, deaths, or AE-related withdrawals were reported; results are preliminary and unblinded.
Single-dose pharmacodynamic changes included FT3/FT4 declines starting on days 2–3 and TSH rises starting on days 3–5; improvements in proptosis and overall response were also observed, with no head-to-head comparisons conducted.
GenSci’s China TED multiple-ascending-dose study is evaluating three dose levels, with topline data expected in 2H 2027; TED development options may follow, including potential initiation of a Phase 2 study.
The planned GD Phase 2b study is designed for 200 participants, with a 24-week primary efficacy readout; doses will be informed by Phase 2a results.
Unmet need and market opportunity
TSHR is the point of convergence in GD and TED; blocking it is designed to address thyroidal and extra-thyroidal disease manifestations while preserving thyroid tissue and function.
The presentation estimates ~34,000–68,000 eligible GD patients and ~11,000–22,000 eligible TED patients annually; it characterizes each as a potential $2B+ US market opportunity.
Current GD treatments have efficacy and tolerability limitations: the presentation cites 50% remission after 12–18 months of ATDs, 50% relapse after discontinuation, and 23% progressing to radioactive iodine or surgery.
For TED, the presentation cites hearing impairment, hyperglycemia, infusion reactions, and relapse after treatment among limitations of existing biologic treatment.
Latest events from Yarrow Bioscience
- DIRECTION-GD and GenSci TED data are expected in H2 2027; cash runway extends into 2030.YARW
Q3 2026 - YB-101 advances dual-indication TSHR blockade, with key data expected in 2H 2027.YARW
3rd Annual Guggenheim Healthcare Innovation Conference - Merger completed, $200M raised, YB-101 trial advanced, and Q2 net loss was $6.5M.YARW
Q2 2026 - YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach.YARW
Investor presentation - Advancing BET inhibitors for autoimmune diseases with robust trials and strong financial runway.YARW
Stifel 2024 Immunology and Inflammation Virtual Summit - Net loss narrowed 58% year-over-year as R&D spending dropped ahead of the Yarrow merger.YARW
Q1 2026 - Losses narrowed in 2025 as the company pivots to a merger with Yarrow and exits key R&D programs.YARW
Q4 2025 - BET inhibitor programs advance in vitiligo and psoriasis, with key clinical readouts expected in 2024.YARW
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - BET inhibitor programs advance in vitiligo and psoriasis, with pivotal data expected in 2024–2025.YARW
TD Cowen 45th Annual Healthcare Conference